A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）

NCT07690332 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancers
Primary Peritoneal Cancer

Interventions

DRUG: Mirvetuximab Soravtansine (MIRV)

Sponsor

NING LI-GYN